The data set collected for this assessment consisted of 160 primary tumors classified under 4 breast cancer molecular subtypes groups in equal sample sizes (luminal A, luminal B, Her2-enriched and basal-like) and 40 matching normal breast tissue biopsies as controls (Cancer Genome Atlas, 2012). This evidence concerns the gene ERBB2 and breast carcinoma.